We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

81 hedge funds and large institutions have $893M invested in Pliant Therapeutics in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

7% more funds holding

Funds holding: 76 → 81 (+5)

0.44% less ownership

Funds ownership: 85.95% → 85.51% (-0.44%)

26% less capital invested

Capital invested by funds: $1.21B → $893M (-$314M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $189K

Holders
81
Holders Change
+5
Holders Change %
+6.58%
% of All Funds
1.41%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
12
Increased
27
Reduced
23
Closed
7
Calls
–
Puts
$189K
Net Calls
-$189K
Net Calls Change
-$189K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$5.26M
2
FIM
Fernwood Investment Management
Massachusetts
+$4.7M
3
BDFN
Bond & Devick Financial Network
Minnesota
+$3.74M
4
WP
Woodline Partners
California
+$2.23M
5
SFM
Sphera Funds Management
Israel
+$1.59M

Top Sellers

1
FCM
Farallon Capital Management
California
-$8.54M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.02M
3
BlackRock
BlackRock
New York
-$3.65M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$3.63M
5
RG
Redmile Group
California
-$1.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP III
Massachusetts
$170M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$157M +$730K +23,440 +0.4%
RG
3
Redmile Group
California
$91.9M -$1.58M -50,792 -2%
EAM
4
Eventide Asset Management
Massachusetts
$72M – – –
CA
5
CHI Advisors
New York
$69M +$1.34M +43,093 +2%
TGI
6
TRV GP IV
Massachusetts
$62.1M – – –
BlackRock
7
BlackRock
New York
$45.4M -$3.65M -117,100 -7%
Vanguard Group
8
Vanguard Group
Pennsylvania
$37M +$5.26M +168,971 +15%
Citadel Advisors
9
Citadel Advisors
Florida
$34.9M -$740K -23,775 -2%
HMC
10
Harvard Management Company
Massachusetts
$16.4M – – –
Bessemer Group
11
Bessemer Group
New Jersey
$15.6M – – –
FCM
12
Farallon Capital Management
California
$14.3M -$8.54M -274,262 -36%
CAM
13
Cormorant Asset Management
Massachusetts
$14M -$4.02M -128,996 -21%
Franklin Resources
14
Franklin Resources
California
$11.5M +$1.45M +46,500 +13%
State Street
15
State Street
Massachusetts
$11.2M +$148K +4,759 +1%
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
$8.7M -$887K -28,501 -9%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$8.21M -$8.59K -276 -0.1%
Northern Trust
18
Northern Trust
Illinois
$6.29M -$186K -5,970 -3%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$6.13M -$108K -3,479 -2%
FIM
20
Fernwood Investment Management
Massachusetts
$4.41M +$4.7M +151,111 New
BDFN
21
Bond & Devick Financial Network
Minnesota
$3.5M +$3.74M +120,160 New
N
22
Nuveen
North Carolina
$3.2M +$923K +29,660 +37%
IC
23
Ikarian Capital
Texas
$3.17M – – –
Charles Schwab
24
Charles Schwab
California
$2.76M +$42.3K +1,358 +1%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$2.61M +$416K +13,374 +18%
1
2 3 4

PLRX Hedge Fund Activity: Q2 2021 in Review

81 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2021, worth a combined $893M — down 26% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PLRX positions and 7 closed out — a net gain of 5 holders — while 27 added to existing stakes and 23 trimmed.

The largest buyer was Vanguard Group, adding an estimated $5.26M. The largest seller was Farallon Capital Management, cutting an estimated $8.54M.

  • 81 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2021, up from 76 in Q1 2021.
  • Funds reported $893M of Pliant Therapeutics stock for Q2 2021, down 26% quarter-over-quarter.
  • 12 funds opened new Pliant Therapeutics positions in Q2 2021 and 7 closed out, a net change of +5 holders.
  • The largest Pliant Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $5.26M added.
  • The largest Pliant Therapeutics seller in Q2 2021 was Farallon Capital Management, an estimated $8.54M sold.

Based on aggregated 13F filings for Q2 2021.